Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis
- 26 December 2007
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 43 (2), 169-174
- https://doi.org/10.1002/ppul.20751
Abstract
Introduction In cystic fibrosis (CF) patients, respiratory syncytial virus (RSV) infection is associated with significant morbidity. Although passive prophylaxis with palivizumab lowers hospitalization rate for RSV infection in populations at risk of severe infection, its use is not recommended in infants with CF disease. Objective To determine the effect of palivizumab prophylaxis on hospitalization for acute respiratory illness in young children with CF during the first RSV season following the diagnosis of CF. Methods In this retrospective study, medical records of patients diagnosed with CF between the years 1997 and 2005 inclusively and on whom the diagnosis was made before 18 months of age were reviewed. Collected data included age at diagnosis, palivizumab prophylaxis, occurrence of hospitalization for acute respiratory tract illness during the RSV season and identification of RSV infection. Results A diagnosis of CF was made in 76 young children and data collected from 75 children. Of those, 40 did not receive RSV prophylaxis while 35 received palivizumab injection monthly during the RSV season. Among non-recipient children, 7 out of 40 were hospitalized for acute respiratory illness during the RSV season. Of these seven patients, RSV detection was positive in nasopharyngeal secretions in three patients, negative in one patient and not requested in the others. Among palivizumab recipients, 3 out of 35 children were hospitalized for acute respiratory illness (P > 0.05 compared to non-recipients group). In these three palivizumab recipients, RSV detection was negative in nasopharyngeal secretions. Palivizumab recipients experienced fewer hospital days per patient for acute respiratory illness (mean ± SD: 0.8 ± 3.07 days) as compared to non-recipients (mean ± SD: 1.73 ± 4.27 days) but this difference did not reach statistical significance. Conclusion CF infants may benefit from RSV immunoprophylaxis with palivizumab. Pediatr Pulmonol. 2008; 43:169–174.Keywords
This publication has 19 references indexed in Scilit:
- Beyond randomized controlled trials: A “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumabPediatric Pulmonology, 2006
- Respiratory Viruses Augment the Adhesion of Bacterial Pathogens to Respiratory Epithelium in a Viral Species- and Cell Type-Dependent MannerJournal of Virology, 2006
- Impaired nitric oxide synthase-2 signaling pathway in cystic fibrosis airway epitheliumAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Respiratory Syncytial Virus–Induced Chemokine Production: Linking Viral Replication to Chemokine Production In Vitro and In VivoThe Journal of Infectious Diseases, 2004
- Effects of upper respiratory tract infections in patients with cystic fibrosis.Thorax, 1996
- Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis.Archives of Disease in Childhood, 1995
- Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms.Thorax, 1989
- Effects of acute viral respiratory tract infections in patients with cystic fibrosisPediatric Pulmonology, 1989
- Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosisThe Journal of Pediatrics, 1988
- Association of Respiratory Viral Infections with Pulmonary Deterioration in Patients with Cystic FibrosisThe New England Journal of Medicine, 1984